- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Two more clinical trials go against Lilly
September 4, 2012
J.K. WallIn the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company
suffered two other setbacks with former stars of its pipeline.
MoreLilly stops testing of experimental schizophrenia drug
August 29, 2012
Bloomberg NewsEli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was
unlikely to show a benefit in patients.
MoreLilly's Alzheimer's finding triggers investor hope, doctor caution
August 27, 2012
Bloomberg NewsWhile investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression
early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
MoreLilly wins appeal upholding patent for Alimta cancer drug
August 24, 2012
Bloomberg NewsEli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and
blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
MoreLilly's Alzheimer's drug trials show mixed results
August 24, 2012
Bloomberg News, J.K. WallEli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials.
However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some
patients.
MoreLilly stock slips after competitors halt Alzheimer's plans
August 7, 2012
IBJ Staff and Bloomberg NewsPfizer Inc., Johnson & Johnson and Elan Corp. are ending most plans to develop an Alzheimer’s drug after a second
trial failure. Eli Lilly is developing a similar treatment.
MoreDespite funding dip, IU bets on brains
August 6, 2012
J.K. WallThe city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million
research center near Methodist Hospital.
MoreMcKesson to pay $151M to settle drug-pricing suit
July 27, 2012
Associated PressTwenty-nine states, including Indiana, have reached a $151 million settlement in a lawsuit alleging one of the country's
largest drug wholesalers inflated prices for hundreds of prescription drugs, officials said Friday.
MoreLilly's quarterly profit falls, but tops analyst expectations
July 25, 2012
Bloomberg NewsEli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook
for the rest of the year.
MorePotential Alzheimer’s drug fails first of four key trials
July 24, 2012
Bloomberg NewsBapineuzumab is in a race with a similar product from Indianapolis-based Eli Lilly and Co. to become the first therapy to
target a cause for Alzheimer’s, rather than just its symptoms.
MorePotential Lilly antipsychotic falls short in study
July 11, 2012
Associated PressEli Lilly and Co. said a potential treatment for acute schizophrenia failed in a late-stage study that compared patients taking
the drug to those taking a placebo.
MoreLilly gets 6-month Cymbalta marketing extension
July 6, 2012
Associated PressEli Lilly and Co. said Friday that it has received an extra six months of marketing exclusivity on the antidepressant Cymbalta,
its biggest selling drug. The extension could mean more than a billion dollars in sales for the Indianapolis drug maker.
MoreLilly cancer treatment fails trial in stomach cancer
July 5, 2012
IBJ Staff and Bloomberg NewsErbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with
advanced stomach tumors in a late-stage clinical trial.
MoreBristol-Myers to buy former Lilly partner Amylin for $5.3B
June 30, 2012
Bloomberg NewsBristol-Myers Squibb Co. has agreed to pay $5.3 billion to acquire former Eli Lilly and Co. partner Amylin Pharmaceuticals
Inc., a maker of diabetes therapies. The deal is valued at about $7 billion, which includes Amylin’s debt and a payment
to Eli Lilly and Co. of about $1.7 billion.
MoreLilly resumes $3B stock buyback program, declares dividend
June 19, 2012
Associated PressThe local pharmaceutical giant plans to complete the program started in 2000 by repurchasing $420 million in shares by the
end of the year. And on Tuesday, it declared a regular dividend of 49 cents.
MoreLilly sinks $20M into Chinese firm for 'branded generic' drugs
June 12, 2012
J.K. WallEli Lilly and Co. has invested $20 million in Chinese pharmaceutical company Novast Labs in an effort to build up a portfolio
of branded generic medicines in the fast-growing Asian market.
MoreLilly chases Novo in insulin race
June 11, 2012
J.K. WallEli Lilly and Co. announced positive results for an experiemental insulin at the annual American Diabetes Association conference
in Philadelphia, but was still upstaged by Denmark-based Novo Nordisk A/S.
MoreFDA’s $6.4B drug review fee plan passes Senate
May 24, 2012
Bloomberg NewsThe U.S. Senate voted to let regulators collect on a $6.4 billion fee agreement struck with Indianapolis-based Eli Lilly and
Co., Medtronic Inc. and other companies to fund reviews of new drugs and medical devices through 2017.
MoreGood cholesterol may not lower heart risk, study suggests
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
MoreU.S. losing drug-research jobs to other countries
May 17, 2012
Bloomberg NewsEli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore,
Ireland and South Africa boost incentives.
MoreLilly unlikely to gain from Plavix patent loss, analyst says
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
MoreRoche scraps hoped-for cholesterol blockbuster
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
MoreLilly: Forget Alzheimer's; think diabetes
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
MoreArrests made in $80M Lilly prescription drug heist
May 3, 2012
IBJ Staff and Associated Press, Bloomberg NewsAuthorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs
from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's
office said Thursday.
MoreLilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.